Evidence map›Paper›PMID 33066346›Full record

ArticleInternational journal of molecular sciences2020

Proteomic Characterization of Urinary Extracellular Vesicles from Kidney-Transplanted Patients Treated with Calcineurin Inhibitors.

Laura Carreras-Planella, Javier Juega, Omar Taco, Laura Cañas, Marcella Franquesa, Ricardo Lauzurica, Francesc Enric Borràs

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 2 pooled it
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Review
  4. Review
  5. Extracellular Vesicles and Immune Activation in Solid Organ Transplantation: The Impact of Immunosuppression.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025
    Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Laura Carreras-PlanellaREMAR-IVECAT Group, Can Ruti Campus, Germans Trias i Pujol Health Science Research Institute, 08916 Badalona, Spain.
Javier JuegaREMAR-IVECAT Group, Can Ruti Campus, Germans Trias i Pujol Health Science Research Institute, 08916 Badalona, Spain.
Omar TacoAutonomous University of Barcelona, Bellaterra, 08193 Cerdanyola del Vallès, Spain.
Laura CañasREMAR-IVECAT Group, Can Ruti Campus, Germans Trias i Pujol Health Science Research Institute, 08916 Badalona, Spain.
Marcella FranquesaREMAR-IVECAT Group, Can Ruti Campus, Germans Trias i Pujol Health Science Research Institute, 08916 Badalona, Spain.ORCID 0000-0002-1287-8908
Ricardo LauzuricaREMAR-IVECAT Group, Can Ruti Campus, Germans Trias i Pujol Health Science Research Institute, 08916 Badalona, Spain.
Francesc Enric BorràsREMAR-IVECAT Group, Can Ruti Campus, Germans Trias i Pujol Health Science Research Institute, 08916 Badalona, Spain.ORCID 0000-0003-4038-1912
Universitat Autònoma de Barcelona · ESInstitut d'Investigació en Ciències de la Salut Germans Trias i Pujol · ESInstituto de Salud Carlos III · ES

Funding

European Regional Development Fund Investing in your futureFundación Cellex PROTEOVEXGeneralitat de Catalunya 2017-SGR-301 REMAR GroupH2020 European Institute of Innovation and Technology PROTEOVEXInstituto de Salud Carlos III MS19/00018Instituto de Salud Carlos III PI13/ 00050Instituto de Salud Carlos III RD16/0009 Feder Funds"la Caixa" Foundation ID 100010434Ministerio de Economía, Industria y Competitividad, Gobierno de España FPU17/01444
6 · The paper itself

Abstract

Use of immunosuppressive drugs is still unavoidable in kidney-transplanted patients. Since their discovery, calcineurin inhibitors (CNI) have been considered the first-line immunosuppressive agents, in spite of their known nephrotoxicity. Chronic CNI toxicity (CNIT) may lead to kidney fibrosis, a threatening scenario for graft survival. However, there is still controversy regarding CNIT diagnosis, monitoring and therapeutic management, and their specific effects at the molecular level are not fully known. Aiming to better characterize CNIT patients, in the present study, we collected urine from kidney-transplanted patients treated with CNI who (i) had a normal kidney function, (ii) suffered CNIT, or (iii) presented interstitial fibrosis and tubular atrophy (IFTA). Urinary extracellular vesicles (uEV) were enriched and the proteome was analyzed to get insight into changes happening during CNI. Members of the uroplakin and plakin families were significantly upregulated in the CNIT group, suggesting an important role in CNIT processes. Although biomarkers cannot be asserted from this single pilot study, our results evidence the potential of uEV as a source of non-invasive protein biomarkers for a better detection and monitoring of this renal alteration in kidney-transplanted patients.

Indexed as

AdultAgedBiomarkersCalcineurin InhibitorsCyclosporineExtracellular VesiclesFemaleFibrosisGraft SurvivalHumansKidneyKidney DiseasesKidney TransplantationMaleMiddle AgedPlakinsBiomarkersCalcineurin InhibitorsCyclosporinePlakinsProteomeTacrolimusUroplakinscyclosporine Aexosomesproteomicsrenal transplantationtacrolimus

Identifiers

PMID33066346
PMCPMC7589460
OpenAlexW3092870822

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.